Polymyalgia Rheumatica
Polymyalgia Rheumatica Market

Polymyalgia Rheumatica is an inflammatory disorder that causes muscle pain and stiffness, especially in the shoulders and hips, and additional generalized systemic symptoms such as fatigue, low-grade fever, and/or a general feeling of ill health (malaise). Signs and symptoms of Polymyalgia Rheumatica usually begin quickly and are worse in the morning. Most people who develop Polymyalgia Rheumatica are older than 65. It rarely affects people under 50. 


Polymyalgia Rheumatica Epidemiological Segmentation 

The Epidemiological Segmentation of Polymyalgia Rheumatica in 7MM from 2018 to 2030 is segmented into:-


  • Total Prevalence of Polymyalgia Rheumatica
  • Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation
  • Gender-specific Prevalence of Polymyalgia Rheumatica
  • Polymyalgia Rheumatica Diagnosed cases of Giant Cell Arteritis (GCA) 


Polymyalgia Rheumatica Epidemiological Insights Observed in 2020


  • The total prevalent cases of Polymyalgia Rheumatica in 7MM were 1,708,823.
  • The prevalent population of Polymyalgia Rheumatica in the United States was observed to be 822,782.
  • The prevalent population of Polymyalgia Rheumatica in France was 224,925.
  • The prevalent population of Polymyalgia Rheumatica in the United Kingdom was observed to be  210,372.
  • The prevalent population of Polymyalgia Rheumatica in Spain was 117,019.
  • The prevalent population of Polymyalgia Rheumatica in Japan was 880.


Polymyalgia Rheumatica Market

The market size of Polymyalgia Rheumatica in the 7MM was found to be USD 2,893.6 million in 2020.


Polymyalgia Rheumatica Market Drivers


  • Treat to target approach
  • Emerging treatment
  • Imaging techniques
  • An increasing number of cases


Polymyalgia Rheumatica Market Barriers


  • Lack of knowledge regarding etiology
  • Lack of specific diagnosis
  • Misdiagnosis


Polymyalgia Rheumatica Emerging Drugs

The emerging drugs of the Polymyalgia Rheumatica market are

  • Tocilizumab
  • Abatacept 
  • Baricitinib, and others


Polymyalgia Rheumatica Key Players

The key players working in the Polymyalgia Rheumatica market are

  • Roche Chugai
  • Bristol-Myers Squibb
  • Eli Lilly, and others